FR3060394B1 - COMBINATION OF ANTI-CD303 AND ANTI-AMHRII ANTIBODIES - Google Patents

COMBINATION OF ANTI-CD303 AND ANTI-AMHRII ANTIBODIES Download PDF

Info

Publication number
FR3060394B1
FR3060394B1 FR1662602A FR1662602A FR3060394B1 FR 3060394 B1 FR3060394 B1 FR 3060394B1 FR 1662602 A FR1662602 A FR 1662602A FR 1662602 A FR1662602 A FR 1662602A FR 3060394 B1 FR3060394 B1 FR 3060394B1
Authority
FR
France
Prior art keywords
combination
antibodies
amhrii antibodies
amhrii
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1662602A
Other languages
French (fr)
Other versions
FR3060394A1 (en
Inventor
Abdessatar Sami Chtourou
Nathalie Fournier
Christophe de Romeuf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Priority to FR1662602A priority Critical patent/FR3060394B1/en
Priority to EP17836011.1A priority patent/EP3555136A1/en
Priority to PCT/EP2017/083156 priority patent/WO2018109209A1/en
Priority to US16/469,173 priority patent/US20200095326A1/en
Publication of FR3060394A1 publication Critical patent/FR3060394A1/en
Application granted granted Critical
Publication of FR3060394B1 publication Critical patent/FR3060394B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

La présente invention concerne une composition pharmaceutique comprenant, dans un véhicule pharmaceutiquement acceptable : a. au moins un anticorps anti-CD303; et b. au moins un anticorps anti-AMHRII. La présente invention est également relative à l'association des deux anticorps a) et b) susmentionnés comme produit de combinaison pour une utilisation simultanée, séparée ou étalée dans le temps, pour son utilisation dans la prévention ou le traitement des cancers urogénitaux.The present invention relates to a pharmaceutical composition comprising, in a pharmaceutically acceptable carrier: a. at least one anti-CD303 antibody; and B. at least one anti-AMHRII antibody. The present invention also relates to the combination of the above two antibodies a) and b) as a combination product for simultaneous, separate or extended use for its use in the prevention or treatment of urogenital cancers.

FR1662602A 2016-12-16 2016-12-16 COMBINATION OF ANTI-CD303 AND ANTI-AMHRII ANTIBODIES Expired - Fee Related FR3060394B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1662602A FR3060394B1 (en) 2016-12-16 2016-12-16 COMBINATION OF ANTI-CD303 AND ANTI-AMHRII ANTIBODIES
EP17836011.1A EP3555136A1 (en) 2016-12-16 2017-12-15 Combination of anti-cd303 and anti-amhrii antibodies
PCT/EP2017/083156 WO2018109209A1 (en) 2016-12-16 2017-12-15 Combination of anti-cd303 and anti-amhrii antibodies
US16/469,173 US20200095326A1 (en) 2016-12-16 2017-12-15 Combination of ant-cd303 and anti-amhrii antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1662602 2016-12-16
FR1662602A FR3060394B1 (en) 2016-12-16 2016-12-16 COMBINATION OF ANTI-CD303 AND ANTI-AMHRII ANTIBODIES

Publications (2)

Publication Number Publication Date
FR3060394A1 FR3060394A1 (en) 2018-06-22
FR3060394B1 true FR3060394B1 (en) 2019-05-24

Family

ID=58401747

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1662602A Expired - Fee Related FR3060394B1 (en) 2016-12-16 2016-12-16 COMBINATION OF ANTI-CD303 AND ANTI-AMHRII ANTIBODIES

Country Status (4)

Country Link
US (1) US20200095326A1 (en)
EP (1) EP3555136A1 (en)
FR (1) FR3060394B1 (en)
WO (1) WO2018109209A1 (en)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
CA2350233A1 (en) 1998-11-02 2000-05-11 Genzyme Transgenics Corp. Transgenic and cloned mammals
NZ518263A (en) 1999-10-14 2004-03-26 Gtc Biotherapeutics Inc Methods of producing a target molecule in a transgenic animal and purification of the target molecule
CN1454215B (en) * 1999-11-15 2013-01-02 米勒腾尼生物技术有限公司 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
EP1565564A4 (en) 2002-11-27 2006-06-07 Gtc Biotherapeutics Inc Modified antibodies stably produced in milk and methods of producing same
WO2005033281A2 (en) 2003-09-30 2005-04-14 Sterrenbeld Biotechnologie North America, Inc. A process of making transgenic mammals that produce exogenous proteins in milk and transgenic mammals produced thereby
US20080003617A1 (en) * 2004-12-20 2008-01-03 Xiaomin Fan Methods for the identification and the isolation of epitope specific antibodies
ES2417147T3 (en) 2005-10-21 2013-08-06 Revo Biologics, Inc. Antibodies with enhanced antibody dependent cell cytotoxicity activity, methods for their production and use
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
RS53861B1 (en) 2006-09-10 2015-08-31 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1918304A1 (en) 2006-11-02 2008-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II)
FR2959994B1 (en) * 2010-05-12 2012-08-24 Lfb Biotechnologies NOVEL 12G4 MUTUS HUMANIZED ANTIBODIES AND THEIR FRAGMENTS DIRECTED AGAINST THE HUMAN TYPE II ANTI-MULLERIAN HORMONE RECEPTOR
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
FR2984750B1 (en) * 2011-12-23 2014-01-10 Lfb Biotechnologies NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING A HUMAN RECEPTOR ANTIBODY OF ANTI-MULLERIAN HORMONE TYPE II
JP6685225B2 (en) * 2013-12-16 2020-04-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Depletion of plasmacytoid dendritic cells
FR3034420A1 (en) * 2015-03-31 2016-10-07 Lab Francais Du Fractionnement ANTI-CD303 MONOCLONAL ANTIBODIES

Also Published As

Publication number Publication date
US20200095326A1 (en) 2020-03-26
EP3555136A1 (en) 2019-10-23
FR3060394A1 (en) 2018-06-22
WO2018109209A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
MA47313A (en) SUBCUTANEOUS FORMULATIONS OF HER2 ANTIBODIES
MA44312A (en) ANTIBODIES AND THEIR METHODS OF USE
MA42622B1 (en) LIAISONS IN TIGIT AND THEIR USES
MA52492B1 (en) RIP1 INHIBITORY COMPOUNDS, METHODS OF PREPARATION AND USE THEREOF
MA39094A1 (en) Combination therapy comprising an inhibitor of mdm2 and one or more additional pharmaceutically active principles for the treatment of cancers
MA34753B1 (en) COMPOSITIONS AND METHODS OF TREATMENT IN LARGE SPECTRUM, INDIFFERENTIATED OR MIXED CLINICAL APPLICATIONS
MA37809A1 (en) Biodegradable drug delivery for hydrophobic compositions
MA30345B1 (en) ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY FORMULATION
FR3065371B1 (en) TOPICAL PHARMACEUTICAL COMPOSITION INCLUDING AT LEAST AMITRIPTYLINE FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN
MA32892B1 (en) Antibodies to cmet
MA43763A (en) PRE-FUSION RSV PROTEIN F SOLUBLE AND STABILIZED FOR USE IN THE PROPHYLAXIS OF RSV INFECTION
MA32458B1 (en) COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER
MA34067B1 (en) COMPOUNDS BASED ON FE (III) COMPLEXES FOR TREATMENT AND PREVENTION OF IRON DEFICIENCIES AND ANEMIA DUE TO IRON DEFICIENCIES
MA34175B1 (en) HUMANIZED ANTI-CXCR4 ANTIBODIES FOR THE TREATMENT OF CANCER
MA34387B1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3- [6- (4-METHYLPIPERRAZIN-1-YL) -1H-BENZIMIDAZOL-2-YL] -1H-QUINOLIN-2-ONE MONOHYDRATE LACTATE
FR2992973B1 (en) NEW STRAIN OF LACTOBACILLUS CRISPATUS
MA52154B1 (en) Pharmaceutical composition for anemia
FR3063645B1 (en) ACEFAPC FOR THE TREATMENT OF ACETYLCHOLINE DEPENDENT DISEASES
MA35281B1 (en) Assay and administration of anti-erbb3 antibodies in combination with paclitaxel for the treatment of gynecological cancers
MA37317B1 (en) Antibody formulation il-17
MA39378A1 (en) Igf-1r antibody and its use as an addressing vehicle for the treatment of cancer
MA54663A1 (en) Aqueous pharmaceutical composition of an anti-il17a antibody and its use
MA43474B1 (en) Formulation systems for antimicrobial glycolipids
FR3060394B1 (en) COMBINATION OF ANTI-CD303 AND ANTI-AMHRII ANTIBODIES
MA46988A1 (en) Liquid formulation of anti-tnf alpha antibodies

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180622

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

ST Notification of lapse

Effective date: 20220808